KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $392.6 million.

  • Resmed's Profit After Tax rose 1391.99% to $392.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 1899.33%. This contributed to the annual value of $1.4 billion for FY2025, which is 3719.79% up from last year.
  • Latest data reveals that Resmed reported Profit After Tax of $392.6 million as of Q4 2025, which was up 1391.99% from $348.5 million recorded in Q3 2025.
  • Resmed's Profit After Tax's 5-year high stood at $392.6 million during Q4 2025, with a 5-year trough of -$78.5 million in Q1 2021.
  • In the last 5 years, Resmed's Profit After Tax had a median value of $227.3 million in 2022 and averaged $247.8 million.
  • In the last 5 years, Resmed's Profit After Tax tumbled by 14810.74% in 2021 and then surged by 32809.6% in 2022.
  • Quarter analysis of 5 years shows Resmed's Profit After Tax stood at $201.8 million in 2021, then rose by 11.48% to $224.9 million in 2022, then fell by 7.16% to $208.8 million in 2023, then skyrocketed by 65.05% to $344.6 million in 2024, then grew by 13.92% to $392.6 million in 2025.
  • Its Profit After Tax was $392.6 million in Q4 2025, compared to $348.5 million in Q3 2025 and $379.7 million in Q2 2025.